Yong-Chan Kim
Direttore/Membro del Consiglio presso BAUDAX BIO, INC.
Patrimonio netto: 32 $ in data 30/06/2024
Posizioni attive di Yong-Chan Kim
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| BAUDAX BIO, INC. | Direttore/Membro del Consiglio | 03/07/2023 | - |
| Independent Dir/Board Member | 03/07/2023 | - | |
TeraImmune, Inc.
 TeraImmune, Inc. BiotechnologyHealth Technology TeraImmune, Inc. engages in the development of customized cell therapies for autoimmune diseases using the patient’s own Treg cells. Its pipeline includes Hemophilia A, Multiple Sclerosis, and B cell lymphoma. The company was founded by Yong-Chan Kim and Ji-Hoon Park in 2016 and is headquartered in Gaithersburg, MD. | Direttore/Membro del Consiglio | 01/04/2019 | - |
| Amministratore Delegato | 01/04/2019 | - | |
| Fondatore | 01/01/2016 | - |
Storia della carriera di Yong-Chan Kim
Formazione di Yong-Chan Kim
| Chungnam National University | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
| Corea del Sud | 2 |
Posizioni
| Director/Board Member | 2 |
| Chief Executive Officer | 1 |
| Founder | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BAUDAX BIO, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
TeraImmune, Inc.
TeraImmune, Inc. BiotechnologyHealth Technology TeraImmune, Inc. engages in the development of customized cell therapies for autoimmune diseases using the patient’s own Treg cells. Its pipeline includes Hemophilia A, Multiple Sclerosis, and B cell lymphoma. The company was founded by Yong-Chan Kim and Ji-Hoon Park in 2016 and is headquartered in Gaithersburg, MD. | Health Technology |
- Borsa valori
- Insiders
- Yong-Chan Kim
- Esperienza
